Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
BCTX BriaCell Therapeutics
5.530
-0.060-1.07%
YOY
Do not show
Hide blank lines
(FY)2022/07/31(Q4)2022/07/31(Q3)2022/04/30(Q2)2022/01/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
119.31% 15.29M 165.92% 4.23M 0.75% 4.85M 1,336.63% 3.93M
Selling and administrative expenses
28.79% 7.27M 37.60% 1.37M -47.76% 2.3M 1,144.40% 2.2M
-General and administrative expense
28.79% 7.27M 37.60% 1.37M -47.76% 2.3M 1,144.40% 2.2M
Research and development costs
509.77% 8.02M 382.61% 2.87M 526.16% 2.54M 1,755.47% 1.73M
Depreciation amortization depletion
-- -- -- -- 0.00% 3.82K 4.18% 3.82K
-Depreciation and amortization
-- -- -- -- 0.00% 3.82K 4.18% 3.82K
Other operating expenses
8.21% -3.39K -- 0 -- -- -- -3.39K
Operating profit
-119.31% -15.29M -165.92% -4.23M -0.75% -4.85M -1,336.63% -3.93M
Net non-operating interest income expense
-26,730.48% -11.52M -14,380.75% -11.58M 157.62% 35.99K 127.45% 12.08K
Non-operating interest income
4,242.05% 136.73K -- 82.36K -- 35.99K -- 12.08K
Non-operating interest expense
-97.88% 979 -- 0 -- 0 -- 0
Total other finance cost
-- 11.66M -- -- -- -- -- --
Other net income (expense)
-100.47% -30.73K 104.45% 53.99K -100.38% -29.68K 51.7K
Gain on sale of security
-100.45% -30.73K 104.45% 53.99K -100.37% -29.68K -- 51.7K
Special income (charges)
-- 0 -- 0 -- 0 -- 0
Income before tax
-6,165.88% -26.84M -478.51% -15.75M -263.96% -4.84M -1,117.43% -3.87M
Income tax
Net income
-6,165.88% -26.84M -478.51% -15.75M -263.96% -4.84M -1,117.43% -3.87M
Net income continuous Operations
-6,165.88% -26.84M -478.51% -15.75M -263.96% -4.84M -1,117.43% -3.87M
Minority interest income
Net income attributable to the parent company
-6,165.88% -26.84M -478.51% -15.75M -263.96% -4.84M -1,117.43% -3.87M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-6,165.88% -26.84M -478.51% -15.75M -263.96% -4.84M -1,117.43% -3.87M
Basic earnings per share
-1,822.22% -1.73 -466.54% -1.01 -151.02% -0.32 41.00% -0.24
Diluted earnings per share
-1,822.22% -1.73 -466.54% -1.01 -151.02% -0.32 41.00% -0.24
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
Unqualified Opinion------

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
CEO: Dr. William Williams, M.D.
Market: NASDAQ
Listing Date: 02/24/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist